Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Hydrocortisone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
Hydrocortisone overview
Hydrocortisone (ATRS-1902) is under development for the treatment of adrenal crisis rescue. It is administered by parenteral route. It is a combination of drug and device. It comprises of liquid stable formulation of hydrocortisone. It acts by targeting glucocorticoid receptor.
Antares Pharma overview
Antares Pharma is a specialty pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceutical products and technologies. The company’s portfolio encompasses around novel therapeutic products for therapy areas related to polyarticular juvenile idiopathic arthritis, severe rheumatoid arthritis, severe recalcitrant psoriasis, migraine and cluster headache. It also develops products to reduce the risk of preterm birth in pregnant women. It caters its subcutaneous injection technology platforms to both generic and branded injectables. Antares Pharma’s injectables are available in disposable multi-dose pen injectors and unit dose containers. The company employs drug delivery systems to advance drug compounds and drug delivery methods. It also focuses on product development programs in partnership with various pharmaceutical companies including Teva Pharmaceutical Industries Ltd, Ferring Pharmaceuticals and AMAG. The company has presence in the US and Switzerland. Antares Pharma is headquartered in Mercer, New Jersey, the US.
For a complete picture of Hydrocortisone’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
